Imago BioSciences Past Earnings Performance
Past criteria checks 0/6
Imago BioSciences's earnings have been declining at an average annual rate of -57.6%, while the Biotechs industry saw earnings growing at 17.4% annually.
Key information
-57.6%
Earnings growth rate
65.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -35.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
No updates
Recent updates
Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans
Nov 08
Imago BioSciences GAAP EPS of -$0.41 beats by $0.09
Aug 12Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Situation
Jul 26Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth
Apr 12We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate
Dec 08Revenue & Expenses Breakdown
How Imago BioSciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -62 | 16 | 47 |
| 30 Jun 22 | 0 | -57 | 15 | 42 |
| 31 Mar 22 | 0 | -52 | 12 | 40 |
| 31 Dec 21 | 0 | -42 | 10 | 32 |
| 30 Sep 21 | 0 | -33 | 9 | 25 |
| 30 Jun 21 | 0 | -26 | 6 | 20 |
| 31 Mar 21 | 0 | -21 | 5 | 16 |
| 31 Dec 20 | 0 | -18 | 3 | 15 |
Quality Earnings: IMGO is currently unprofitable.
Growing Profit Margin: IMGO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if IMGO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare IMGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMGO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: IMGO has a negative Return on Equity (-35.71%), as it is currently unprofitable.